Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients

Factors Predicting Requirement of High-dose Transdermal Fentanyl in Opioid Switching From Oral Morphine or Oxycodone in Patients With Cancer Pain

“…Earlier research identified differences in transdermal fentanyl absorption for different diseases. 11,12 Solassol et al 12 stated that there was a significant difference in the percentage of absorbed fentanyl according to the type of cancer and absorption was higher in patients with breast or digestive cancer than in those with lung cancer. In contrast, our study found that breast cancer patients required highdose transdermal fentanyl when undergoing opioid switching.…”

Validated GC–MS analysis for the determination of residual fentanyl in applied Durogesic® reservoir and Durogesic® D-Trans® matrix transdermal fentanyl patches

“…Most recently, a study by Solassol et al [13] focused on the inter-and intra-individual variability in transdermal fentanyl absorption in cancer patients. Prior to analysis, the used patches were incised and fentanyl was extracted by mechanical shaking with 50 ml of 1 M hydrochloric acid during 24 h. The necessary time to achieve total fentanyl dissolution from the patches was determined by the establishment of a fentanyl recovery versus time profile of three unused 75-g/h patches.…”

“…Determination of the actual fentanyl delivery rate requires an accurate estimate of both the initial and residual fentanyl content in the transdermal system applied. However, few studies have focussed on this type of assay as a measure of actual delivered transdermal dose from reservoir type patches [10][11][12][13]. Sample preparation protocols in these studies included both water and alcohol based extractions of the TTSs in which the recovery of fentanyl was induced by incision, cutting or simple immersion of the patches.…”

A Retrospective Study on the Influence of Nutritional Status on Pain Management in Cancer Patients Using the Transdermal Fentanyl Patch

“…Thus, some cancer patients receiving the transdermal FP may have unsuccessful pain control. 3) In addition, some factors such as fever and body mass index (BMI) have been reported to influence the residual fentanyl content of used patches, 4,5) suggesting that these factors may affect the transdermal absorption of fentanyl from the patch.…”